Investor Relations

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
 
natera

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

June 29, 2022
Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study
Statistically significant performance improvement from using both dd-cfDNA fraction and dd-cfDNA quantity vs. dd-cfDNA alone AUSTIN, Texas , June 29, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of a manuscript
June 8, 2022
Natera Showcases Leadership in Transplantation at ATC 2022 with New Data on its Prospera and Renasight Tests
Includes oral presentation on Prospera test's two-threshold algorithm, showing the combination of donor quantity and donor fraction outperforms donor fraction alone AUSTIN, Texas , June 8, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today
May 31, 2022
Natera to Present New Signatera™ Clinical Data Across Multiple Cancer Types at the 2022 ASCO Annual Meeting
NSCLC:  ctDNA data in stage I-III patients showed 82% detection pre-treatment and was able to identify 100% of relapses prior to radiographic imaging (5.4 mo lead time)  Breast Cancer: Data from the largest longitudinal ctDNA cohort to date (>1100 samples) showed Signatera's ability to detect
May 24, 2022
Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology
AUSTIN, Texas , May 24, 2022  /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu , M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical
May 16, 2022
Matthew Rabinowitz, Natera Co-Founder and Executive Chairman of the Board, Makes Additional Investment in Natera
AUSTIN, Texas , May 16, 2022 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that Matthew Rabinowitz , co-founder and Executive Chairman of Natera, together with his family's trust, have recently acquired a total of 470,000 shares of Natera stock

Upcoming Events

More events are coming soon.

Past events